BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
UBS
Baxter
Argus Health
Teva
Daiichi Sankyo
Covington
Fuji
Mallinckrodt
Merck

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,572,920

« Back to Dashboard

Summary for Patent: 7,572,920
Title:Benzimidazole derivative and use as a II receptor antagonist
Abstract:The present invention relates to a compound represented by the formula (I) ##STR00001## wherein R.sup.1 is a group represented by the formula ##STR00002## wherein R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are each independently a hydrogen atom or a C.sub.1-6 alkyl, or a salt thereof. The compound of the present invention is useful as an agent for the prophylaxis or treatment of circulatory diseases such as hypertension and the like and metabolic diseases such as diabetes and the like.
Inventor(s): Kuroita; Takanobu (Katano, JP), Sakamoto; Hiroki (Amagasaki, JP), Ojima; Mami (Amagasaki, JP)
Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:11/466,633
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;

Drugs Protected by US Patent 7,572,920

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Arbor Pharms Llc EDARBI azilsartan kamedoxomil TABLET;ORAL 200796-001 Feb 25, 2011 RX Yes No ➤ Subscribe ➤ Subscribe Y TREATMENT OF HYPERTENSION ➤ Subscribe
Arbor Pharms Llc EDARBI azilsartan kamedoxomil TABLET;ORAL 200796-002 Feb 25, 2011 RX Yes Yes ➤ Subscribe ➤ Subscribe Y TREATMENT OF HYPERTENSION ➤ Subscribe
Arbor Pharms Llc EDARBYCLOR azilsartan kamedoxomil; chlorthalidone TABLET;ORAL 202331-001 Dec 20, 2011 RX Yes No ➤ Subscribe ➤ Subscribe Y TREATMENT OF HYPERTENSION ➤ Subscribe
Arbor Pharms Llc EDARBYCLOR azilsartan kamedoxomil; chlorthalidone TABLET;ORAL 202331-002 Dec 20, 2011 RX Yes Yes ➤ Subscribe ➤ Subscribe Y TREATMENT OF HYPERTENSION ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,572,920

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2004-048928Feb 25, 2004

Non-Orange Book US Patents Family Members for Patent 7,572,920

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,157,584 Benzimidazole derivative and use thereof ➤ Subscribe
7,875,637 Benzimidazole derivative and use as a II receptor antagonist ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,572,920

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation 2369608 ➤ Subscribe
Russian Federation 2006133898 ➤ Subscribe
Serbia 52376 ➤ Subscribe
Serbia 51137 ➤ Subscribe
Serbia 50537 ➤ Subscribe
Portugal 2119715 ➤ Subscribe
Portugal 1857457 ➤ Subscribe
Portugal 1718641 ➤ Subscribe
New Zealand 549755 ➤ Subscribe
Norway 2012017 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Citi
Boehringer Ingelheim
Deloitte
Queensland Health
Argus Health
McKinsey
Mallinckrodt
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot